Background and objective. In multiple myeloma (MIM) patients treated with c
onventional chemotherapy, the attainment and duration of a plateau phase se
ems to affect survival more than the degree of response to initial treatmen
t. The aims of this study are: 1) to analyze within a cohort of previously
untreated MM patients the incidence and the duration of the plateau phase;
2) to correlate It with the presenting features; 3) to assess ifs impact on
survival.
Design and Methods A series of 146 consecutive MM patients treated with con
ventional chemotherapy were evaluated far this study. Of 146 patients, 102
responded (13 achieving complete response, 21 partial response, and 68 mini
mal response), and 44 showed less than minimal response or a progression. A
plateau phase was documented in 115 patients (comprising all responders an
d 13 non responders. The median plateau phase duration was 21.6 months. The
majority of patients received Intermittent cycles of chemotherapy (melphal
an or interferon) during the plateau phase. In multivariate analysis, lytic
lesions, response, and time to the best response (TBR) correlated with the
attainment of a plateau, while stage, response as a whole, and TBR showed
a significant correlation with the duration. In contrast, the type of respo
nse did not correlate with either the attainment or the duration of plateau
. To analyze the prognostic impact of presenting features, response to ther
apy and plateau we used a hierarchical model for survival. The analysis sho
wed that the response to therapy and the duration of plateau significantly
affect the survival.
Interpretation and Conclusions In multiple myeloma a plateau phase of at le
ast 6 months' duration has a higher impact an survival than the degree of r
esponse to conventional chemotherapy so plateau duration could be used as t
arget of therapeutic trials. The best way to maintain the plateau phase rem
ains, however, undefined. (C) 1999, Ferrata Storti Foundation.